Article Text

This article has a correction. Please see:

Download PDFPDF
Novel treatment (new drug/intervention; established drug/procedure in new situation)
Plasmapheresis as rescue therapy for systemic lupus erthyematosus-associated diffuse alveolar haemorrhage
  1. Simon Claridge1,
  2. Partha Das2,
  3. Anthony Dorling2,
  4. Michael Robson2
  1. 1Department of Renal, Guy’s and St Thomas’ Hospital Trust, London, UK
  2. 2Department of Nephrology and Transplantation, Guy’s and St Thomas’ Hospital Trust, London, UK
  1. Correspondence to Dr Simon Claridge, simonclaridge{at}doctors.org.uk

Summary

Diffuse alveolar haemorrhage (DAH) is a rare complication of systemic lupus erythematosus (SLE), which can have a potentially lethal outcome. Conventional treatments of the condition include cyclophosphamide and intravenous immunoglobulins. Successful treatment with rituximab and plasmapheresis has also been described. The authors report the case of a woman recently diagnosed with SLE who developed DAH refractory to conventional treatment while on immunosuppressive treatment for class III lupus nephritis whose DAH responded to plasmapheresis.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Competing interests None.

  • Patient consent Obtained.

Linked Articles

  • CORRECTION
    BMJ Publishing Group Ltd